logo-loader
viewTiziana Life Sciences

Tiziana's Foralumab can be biggest disruptor to medical industry 'in a decade'

Chairman and founder of Tiziana Life Sciences plc (LON:TILS) Gabriele Cerrone introduces Proactive London's Andrew Scott to their two lead programmes - one focused on liver cancer and the other on autoimmune diseases.

Tiziana's recently completed two critical clinical trials with data expected in the coming weeks.

Last November it dual-listed on NASDAQ and in the process raised £3.42mln.

Quick facts: Tiziana Life Sciences

Price: 41 GBX

AIM:TILS
Market: AIM
Market Cap: £55.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Southern Gold active on the ground in South Korea with multiple rigs and...

Southern Gold Limited's (ASX:SAU) managing director Simon Mitchell tells Proactive London's Andrew Scott they're looking to become recognised as the go-to name for exploration in South Korea.  ''We're now 100% focused on South Korea and I think that's been well received by the market to...

19 minutes ago

2 min read